Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at William Blair.
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 [Yahoo! Finance]
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]